Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

New targets to modulate the DNA damage response.

Mercurio C, Varasi M.

Future Med Chem. 2018 Oct;10(20):2377-2380. doi: 10.4155/fmc-2018-0231. Epub 2018 Oct 16. No abstract available.

PMID:
30325211
2.

New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors.

La Regina G, Bai R, Coluccia A, Naccarato V, Famiglini V, Nalli M, Masci D, Verrico A, Rovella P, Mazzoccoli C, Da Pozzo E, Cavallini C, Martini C, Vultaggio S, Dondio G, Varasi M, Mercurio C, Hamel E, Lavia P, Silvestri R.

Eur J Med Chem. 2018 May 25;152:283-297. doi: 10.1016/j.ejmech.2018.04.042. Epub 2018 Apr 25.

PMID:
29730191
3.

Non-conventional role of haemoglobin beta in breast malignancy.

Ponzetti M, Capulli M, Angelucci A, Ventura L, Monache SD, Mercurio C, Calgani A, Sanità P, Teti A, Rucci N.

Br J Cancer. 2017 Sep 26;117(7):994-1006. doi: 10.1038/bjc.2017.247. Epub 2017 Aug 3.

4.

Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.

Trifirò P, Cappa A, Brambillasca S, Botrugno OA, Cera MR, Zuffo RD, Dessanti P, Meroni G, Thaler F, Villa M, Minucci S, Mercurio C, Varasi M, Vianello P.

Future Med Chem. 2017 Jul;9(11):1161-1174. doi: 10.4155/fmc-2017-0003. Epub 2017 Jul 19.

PMID:
28722470
5.

3-Aroyl-1,4-diarylpyrroles Inhibit Chronic Myeloid Leukemia Cell Growth through an Interaction with Tubulin.

La Regina G, Bai R, Coluccia A, Famiglini V, Passacantilli S, Naccarato V, Ortar G, Mazzoccoli C, Ruggieri V, Agriesti F, Piccoli C, Tataranni T, Nalli M, Brancale A, Vultaggio S, Mercurio C, Varasi M, Saponaro C, Sergio S, Maffia M, Coluccia AML, Hamel E, Silvestri R.

ACS Med Chem Lett. 2017 Apr 26;8(5):521-526. doi: 10.1021/acsmedchemlett.7b00022. eCollection 2017 May 11.

6.

Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship.

Vianello P, Sartori L, Amigoni F, Cappa A, Fagá G, Fattori R, Legnaghi E, Ciossani G, Mattevi A, Meroni G, Moretti L, Cecatiello V, Pasqualato S, Romussi A, Thaler F, Trifiró P, Villa M, Botrugno OA, Dessanti P, Minucci S, Vultaggio S, Zagarrí E, Varasi M, Mercurio C.

J Med Chem. 2017 Mar 9;60(5):1693-1715. doi: 10.1021/acs.jmedchem.6b01019. Epub 2017 Feb 27.

PMID:
28186757
7.

Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration.

Sartori L, Mercurio C, Amigoni F, Cappa A, Fagá G, Fattori R, Legnaghi E, Ciossani G, Mattevi A, Meroni G, Moretti L, Cecatiello V, Pasqualato S, Romussi A, Thaler F, Trifiró P, Villa M, Vultaggio S, Botrugno OA, Dessanti P, Minucci S, Zagarrí E, Carettoni D, Iuzzolino L, Varasi M, Vianello P.

J Med Chem. 2017 Mar 9;60(5):1673-1692. doi: 10.1021/acs.jmedchem.6b01018. Epub 2017 Feb 27.

PMID:
28186755
8.

Dual modulation of MCL-1 and mTOR determines the response to sunitinib.

Elgendy M, Abdel-Aziz AK, Renne SL, Bornaghi V, Procopio G, Colecchia M, Kanesvaran R, Toh CK, Bossi D, Pallavicini I, Perez-Gracia JL, Lozano MD, Giandomenico V, Mercurio C, Lanfrancone L, Fazio N, Nole F, Teh BT, Renne G, Minucci S.

J Clin Invest. 2017 Jan 3;127(1):153-168. doi: 10.1172/JCI84386. Epub 2016 Nov 28.

9.

Compounds and methods for inhibiting histone demethylases: a patent evaluation of US20160102096A1.

Thaler F, Mercurio C.

Expert Opin Ther Pat. 2016 Dec;26(12):1367-1370. Epub 2016 Oct 21.

PMID:
27730846
10.

Preeclampsia: Long-term effects on pediatric disability.

Nicolás C, Benítez PR, Riaño MO, Canencia LM, Mercurio C, Fernández MS, Luna MS, Jorge AT.

J Neonatal Perinatal Med. 2016;9(1):41-8. doi: 10.3233/NPM-16915065.

PMID:
27002269
11.

Automated Real-Time Conjunctival Microvasculature Image Stabilization.

Felder AE, Mercurio C, Wanek J, Ansari R, Shahidi M.

IEEE Trans Med Imaging. 2016 Jul;35(7):1670-5. doi: 10.1109/TMI.2016.2522918. Epub 2016 Feb 3.

12.

Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent.

Vianello P, Botrugno OA, Cappa A, Dal Zuffo R, Dessanti P, Mai A, Marrocco B, Mattevi A, Meroni G, Minucci S, Stazi G, Thaler F, Trifiró P, Valente S, Villa M, Varasi M, Mercurio C.

J Med Chem. 2016 Feb 25;59(4):1501-17. doi: 10.1021/acs.jmedchem.5b01209. Epub 2016 Jan 7.

PMID:
26702542
13.

Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.

Thaler F, Moretti L, Amici R, Abate A, Colombo A, Carenzi G, Fulco MC, Boggio R, Dondio G, Gagliardi S, Minucci S, Sartori L, Varasi M, Mercurio C.

Eur J Med Chem. 2016 Jan 27;108:53-67. doi: 10.1016/j.ejmech.2015.11.010. Epub 2015 Nov 11.

PMID:
26629860
14.

New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer.

La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Verrico A, Miele A, Monti L, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Ricci B, Soriani A, Santoni A, Caraglia M, Porto S, Da Pozzo E, Martini C, Brancale A, Marinelli L, Novellino E, Vultaggio S, Varasi M, Mercurio C, Bigogno C, Dondio G, Hamel E, Lavia P, Silvestri R.

J Med Chem. 2015 Aug 13;58(15):5789-807. doi: 10.1021/acs.jmedchem.5b00310. Epub 2015 Jul 20.

15.

Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts.

Valente S, Rodriguez V, Mercurio C, Vianello P, Saponara B, Cirilli R, Ciossani G, Labella D, Marrocco B, Monaldi D, Ruoppolo G, Tilset M, Botrugno OA, Dessanti P, Minucci S, Mattevi A, Varasi M, Mai A.

Eur J Med Chem. 2015 Apr 13;94:163-74. doi: 10.1016/j.ejmech.2015.02.060. Epub 2015 Mar 3.

PMID:
25768700
16.

Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies.

Valente S, Rodriguez V, Mercurio C, Vianello P, Saponara B, Cirilli R, Ciossani G, Labella D, Marrocco B, Ruoppolo G, Botrugno OA, Dessanti P, Minucci S, Mattevi A, Varasi M, Mai A.

ACS Med Chem Lett. 2014 Dec 8;6(2):173-7. doi: 10.1021/ml500424z. eCollection 2015 Feb 12.

17.

Further insights into the SAR of α-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A.

Pieroni M, Annunziato G, Azzali E, Dessanti P, Mercurio C, Meroni G, Trifiró P, Vianello P, Villa M, Beato C, Varasi M, Costantino G.

Eur J Med Chem. 2015 Mar 6;92:377-86. doi: 10.1016/j.ejmech.2014.12.032. Epub 2015 Jan 7.

PMID:
25585008
18.

Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner.

Elgendy M, Ciro M, Abdel-Aziz AK, Belmonte G, Dal Zuffo R, Mercurio C, Miracco C, Lanfrancone L, Foiani M, Minucci S.

Nat Commun. 2014 Dec 4;5:5637. doi: 10.1038/ncomms6637.

19.

Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.

Vianello P, Botrugno OA, Cappa A, Ciossani G, Dessanti P, Mai A, Mattevi A, Meroni G, Minucci S, Thaler F, Tortorici M, Trifiró P, Valente S, Villa M, Varasi M, Mercurio C.

Eur J Med Chem. 2014 Oct 30;86:352-63. doi: 10.1016/j.ejmech.2014.08.068. Epub 2014 Aug 27.

PMID:
25173853
20.

New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.

La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Sisinni L, Bolognesi A, Rensen WM, Miele A, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Brancale A, Novellino E, Dondio G, Vultaggio S, Varasi M, Mercurio C, Hamel E, Lavia P, Silvestri R.

J Med Chem. 2014 Aug 14;57(15):6531-52. doi: 10.1021/jm500561a. Epub 2014 Jul 29.

21.

Efficacy of standard (SLA) and modified sandblasted and acid-etched (SLActive) dental implants in promoting immediate and/or early occlusal loading protocols: a systematic review of prospective studies.

Chambrone L, Shibli JA, Mercúrio CE, Cardoso B, Preshaw PM.

Clin Oral Implants Res. 2015 Apr;26(4):359-370. doi: 10.1111/clr.12347. Epub 2014 Feb 21.

PMID:
24814519
22.

Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2-amino-7-[4-fluoro-2-(3-pyridyl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one oxime.

Amici R, Bigogno C, Boggio R, Colombo A, Courtney SM, Dal Zuffo R, Dondio G, Fusar F, Gagliardi S, Minucci S, Molteni M, Montalbetti CA, Mortoni A, Varasi M, Vultaggio S, Mercurio C.

ChemMedChem. 2014 Jul;9(7):1574-85. doi: 10.1002/cmdc.201400037. Epub 2014 Apr 17.

PMID:
24753447
23.

Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.

Thaler F, Mercurio C.

ChemMedChem. 2014 Mar;9(3):523-6. doi: 10.1002/cmdc.201300413. Review.

PMID:
24730063
24.

Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.

Guandalini L, Balliu M, Cellai C, Martino MV, Nebbioso A, Mercurio C, Carafa V, Bartolucci G, Dei S, Manetti D, Teodori E, Scapecchi S, Altucci L, Paoletti F, Romanelli MN.

Eur J Med Chem. 2013 Aug;66:56-68. doi: 10.1016/j.ejmech.2013.05.017. Epub 2013 May 31.

PMID:
23792316
25.

Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.

Thaler F, Varasi M, Abate A, Carenzi G, Colombo A, Bigogno C, Boggio R, Zuffo RD, Rapetti D, Resconi A, Regalia N, Vultaggio S, Dondio G, Gagliardi S, Minucci S, Mercurio C.

Eur J Med Chem. 2013 Jun;64:273-84. doi: 10.1016/j.ejmech.2013.03.061. Epub 2013 Apr 10.

PMID:
23644210
26.

tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.

Valente S, Trisciuoglio D, Tardugno M, Benedetti R, Labella D, Secci D, Mercurio C, Boggio R, Tomassi S, Di Maro S, Novellino E, Altucci L, Del Bufalo D, Mai A, Cosconati S.

ChemMedChem. 2013 May;8(5):800-11. doi: 10.1002/cmdc.201300005. Epub 2013 Mar 25.

PMID:
23526814
27.

Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.

Albanese C, Alzani R, Amboldi N, Degrassi A, Festuccia C, Fiorentini F, Gravina G, Mercurio C, Pastori W, Brasca M, Pesenti E, Galvani A, Ciomei M.

Br J Pharmacol. 2013 May;169(1):156-66. doi: 10.1111/bph.12112.

28.

Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.

La Regina G, Bai R, Rensen WM, Di Cesare E, Coluccia A, Piscitelli F, Famiglini V, Reggio A, Nalli M, Pelliccia S, Da Pozzo E, Costa B, Granata I, Porta A, Maresca B, Soriani A, Iannitto ML, Santoni A, Li J, Miranda Cona M, Chen F, Ni Y, Brancale A, Dondio G, Vultaggio S, Varasi M, Mercurio C, Martini C, Hamel E, Lavia P, Novellino E, Silvestri R.

J Med Chem. 2013 Jan 10;56(1):123-49. doi: 10.1021/jm3013097. Epub 2012 Dec 27.

29.

Spiro[chromane-2,4'-piperidine]-based histone deacetylase inhibitors with improved in vivo activity.

Thaler F, Varasi M, Carenzi G, Colombo A, Abate A, Bigogno C, Boggio R, Carrara S, Cataudella T, Dal Zuffo R, Reali V, Vultaggio S, Dondio G, Gagliardi S, Minucci S, Mercurio C.

ChemMedChem. 2012 Apr;7(4):709-21. doi: 10.1002/cmdc.201200024. Epub 2012 Feb 22.

PMID:
22354629
30.

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.

Leiva M, Moretti S, Soilihi H, Pallavicini I, Peres L, Mercurio C, Dal Zuffo R, Minucci S, de Thé H.

Leukemia. 2012 Jul;26(7):1630-7. doi: 10.1038/leu.2012.39. Epub 2012 Feb 15.

PMID:
22333881
31.

Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability.

La Regina G, Bai R, Rensen W, Coluccia A, Piscitelli F, Gatti V, Bolognesi A, Lavecchia A, Granata I, Porta A, Maresca B, Soriani A, Iannitto ML, Mariani M, Santoni A, Brancale A, Ferlini C, Dondio G, Varasi M, Mercurio C, Hamel E, Lavia P, Novellino E, Silvestri R.

J Med Chem. 2011 Dec 22;54(24):8394-406. doi: 10.1021/jm2012886. Epub 2011 Nov 21.

32.

Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.

Varasi M, Thaler F, Abate A, Bigogno C, Boggio R, Carenzi G, Cataudella T, Dal Zuffo R, Fulco MC, Rozio MG, Mai A, Dondio G, Minucci S, Mercurio C.

J Med Chem. 2011 Apr 28;54(8):3051-64. doi: 10.1021/jm200146u. Epub 2011 Apr 1.

PMID:
21417419
33.

Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer.

Di Micco R, Sulli G, Dobreva M, Liontos M, Botrugno OA, Gargiulo G, dal Zuffo R, Matti V, d'Ario G, Montani E, Mercurio C, Hahn WC, Gorgoulis V, Minucci S, d'Adda di Fagagna F.

Nat Cell Biol. 2011 Mar;13(3):292-302. doi: 10.1038/ncb2170. Epub 2011 Feb 20.

34.

Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples.

Fanelli M, Amatori S, Barozzi I, Soncini M, Dal Zuffo R, Bucci G, Capra M, Quarto M, Dellino GI, Mercurio C, Alcalay M, Viale G, Pelicci PG, Minucci S.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21535-40. doi: 10.1073/pnas.1007647107. Epub 2010 Nov 24.

35.

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, Festuccia C, Fiorentini F, Locatelli G, Pastori W, Patton V, Roletto F, Colotta F, Galvani A, Isacchi A, Moll J, Pesenti E, Mercurio C, Ciomei M.

Mol Cancer Ther. 2010 Aug;9(8):2243-54. doi: 10.1158/1535-7163.MCT-10-0190. Epub 2010 Aug 3.

36.

Design and synthesis of novel isoxazole-based HDAC inhibitors.

Conti P, Tamborini L, Pinto A, Sola L, Ettari R, Mercurio C, De Micheli C.

Eur J Med Chem. 2010 Sep;45(9):4331-8. doi: 10.1016/j.ejmech.2010.06.035. Epub 2010 Jun 30.

PMID:
20637529
37.

Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.

Thaler F, Varasi M, Colombo A, Boggio R, Munari D, Regalia N, Rozio MG, Reali V, Resconi AE, Mai A, Gagliardi S, Dondio G, Minucci S, Mercurio C.

ChemMedChem. 2010 Aug 2;5(8):1359-72. doi: 10.1002/cmdc.201000166.

PMID:
20572281
38.

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.

Locatelli G, Bosotti R, Ciomei M, Brasca MG, Calogero R, Mercurio C, Fiorentini F, Bertolotti M, Scacheri E, Scaburri A, Galvani A, Pesenti E, De Baere T, Soria JC, Lazar V, Isacchi A.

Mol Cancer Ther. 2010 May;9(5):1265-73. doi: 10.1158/1535-7163.MCT-09-1163. Epub 2010 Apr 27.

39.

Histone deacetylases and epigenetic therapies of hematological malignancies.

Mercurio C, Minucci S, Pelicci PG.

Pharmacol Res. 2010 Jul;62(1):18-34. doi: 10.1016/j.phrs.2010.02.010. Epub 2010 Feb 26. Review.

PMID:
20219679
40.

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, Bischoff J, Borghi D, Casale E, Croci V, Fiorentini F, Isacchi A, Mercurio C, Nesi M, Orsini P, Pastori W, Pesenti E, Pevarello P, Roussel P, Varasi M, Volpi D, Vulpetti A, Ciomei M.

Bioorg Med Chem. 2010 Mar 1;18(5):1844-53. doi: 10.1016/j.bmc.2010.01.042. Epub 2010 Jan 25.

PMID:
20153204
41.

Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.

Traquandi G, Ciomei M, Ballinari D, Casale E, Colombo N, Croci V, Fiorentini F, Isacchi A, Longo A, Mercurio C, Panzeri A, Pastori W, Pevarello P, Volpi D, Roussel P, Vulpetti A, Brasca MG.

J Med Chem. 2010 Mar 11;53(5):2171-87. doi: 10.1021/jm901710h.

PMID:
20141146
42.

Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.

Thaler F, Colombo A, Mai A, Amici R, Bigogno C, Boggio R, Cappa A, Carrara S, Cataudella T, Fusar F, Gianti E, di Ventimiglia SJ, Moroni M, Munari D, Pain G, Regalia N, Sartori L, Vultaggio S, Dondio G, Gagliardi S, Minucci S, Mercurio C, Varasi M.

J Med Chem. 2010 Jan 28;53(2):822-39. doi: 10.1021/jm901502p.

PMID:
20017493
43.

Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.

Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G, Colombo M, Colotta F, Croci V, D'Alessio R, Fiorentini F, Isacchi A, Mercurio C, Moretti W, Panzeri A, Pastori W, Pevarello P, Quartieri F, Roletto F, Traquandi G, Vianello P, Vulpetti A, Ciomei M.

J Med Chem. 2009 Aug 27;52(16):5152-63. doi: 10.1021/jm9006559.

PMID:
19603809
44.

Fragment-based identification of Hsp90 inhibitors.

Barker JJ, Barker O, Boggio R, Chauhan V, Cheng RK, Corden V, Courtney SM, Edwards N, Falque VM, Fusar F, Gardiner M, Hamelin EM, Hesterkamp T, Ichihara O, Jones RS, Mather O, Mercurio C, Minucci S, Montalbetti CA, Müller A, Patel D, Phillips BG, Varasi M, Whittaker M, Winkler D, Yarnold CJ.

ChemMedChem. 2009 Jun;4(6):963-6. doi: 10.1002/cmdc.200900011.

PMID:
19301319
45.

Triazole-modified histone deacetylase inhibitors as a rapid route to drug discovery.

Pirali T, Pagliai F, Mercurio C, Boggio R, Canonico PL, Sorba G, Tron GC, Genazzani AA.

J Comb Chem. 2008 Sep-Oct;10(5):624-7. doi: 10.1021/cc800061c. Epub 2008 Jul 4. No abstract available.

PMID:
18598089
46.

[Paleopathology of the natural mummies of the inner Abruzzo region (XVIII-XIX century)].

Ventura L, Miranda G, Mercurio C, Ciocca F, Fornaciari G.

Med Secoli. 2006;18(3):875-96. Italian.

PMID:
18175627
47.

6-Substituted pyrrolo[3,4-c]pyrazoles: an improved class of CDK2 inhibitors.

Brasca MG, Albanese C, Amici R, Ballinari D, Corti L, Croci V, Fancelli D, Fiorentini F, Nesi M, Orsini P, Orzi F, Pastori W, Perrone E, Pesenti E, Pevarello P, Riccardi-Sirtori F, Roletto F, Roussel P, Varasi M, Vulpetti A, Mercurio C.

ChemMedChem. 2007 Jun;2(6):841-52.

PMID:
17450625
48.

Cross platform microarray analysis for robust identification of differentially expressed genes.

Bosotti R, Locatelli G, Healy S, Scacheri E, Sartori L, Mercurio C, Calogero R, Isacchi A.

BMC Bioinformatics. 2007 Mar 8;8 Suppl 1:S5.

49.

Genetic predisposition to rheumatoid arthritis in a Tuscan (Italy) ancient human remain.

Fontecchio G, Fioroni MA, Azzarone R, Battistoni C, Cervelli C, Ventura L, Mercurio C, Fornaciari G, Papola F.

Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):103-9.

PMID:
17346433
50.

Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers.

Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J, McArthur GA.

Cancer Res. 2006 Aug 15;66(16):8219-26.

Supplemental Content

Loading ...
Support Center